MS1819 Lipase

  • Yeast derived recombinant lipase enzyme
  • Oral non-systemic capsule for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis or chronic pancreatitis
  • Superior in vitro characteristics (i.e. high potency, activity in long chain fats, stability in protease and bile salt environments) to pig lipase
  • Supply chain immune to pandemic infection to pig herds
  • Eliminates pork viral contamination risk
  • Vegetarian/Kosher/Halal capsules suitable for all patients including those allergic to pig proteins
  • Available clinical safety and efficacy profile shows promise

 

FW-420 and FW-1022 Niclosamide

  • Novel anti-inflammatory and anti-viral properties
  • Not systemically absorbed
  • Allows for higher local GI concentrations
  • Avoids steroid-related complications
  • Reduced particle size (~7 𝜇𝑚) compared to regular non-micronized (~60 𝜇𝑚) niclosamide
  • Smaller particles have greater surface to solvent (GI fluids) ratio
  • Improved dissolution: broader distribution and higher local GI concentrations
  • Preclinical studies confirm higher GI concentrations (~200x) with micronized niclosamide
  • Niclosamide has a historically clean safety profile – approved by the FDA in 1982 and used on millions of patients